
With the Dividend Data connector, your AI app answers from the same data as this page and links the page behind each number. A free Dividend Data account connects.
Questions to try

GSK (NYSE: GSK) Chief Financial Officer Julie Brown said oncology products could help close the gap between analysts' sales expectations and the company's target of more than £40 billion in annual sales by 2031, as it accelerates drug development and cuts costs. Speaking at the 2026 U.K. Leaders Conference, Brown said GSK expects to complete 22

GSK gains FDA accelerated approval for Nelkarmi in advanced ALK-positive lung cancer, strengthening its oncology portfolio.

GSK can now launch a new medicine in the U.S. for lung cancer, a move that bolsters its efforts to build a franchise in a disease that is the leading cause of cancer death.

GSK NYSE: GSK Chief Financial Officer Julie Brown said oncology products could help close the gap between analysts' sales expectations and the company's target of more than £40 billion in annual sales by 2031, as it accelerates drug development and cuts costs.

FDA grants accelerated approval to GSK's lung cancer drug


GSK NYSE: GSK expects to grow through the loss of patent protection for key HIV medicines, relying on a pipeline of new treatments, an expanding oncology business and continued dealmaking, President of Business Development David Redfern said at the Jefferies Healthcare Conference.

GSK started 18 phase 3 clinical trials in 2026. Specialty medicine sales grew 15% in the third quarter.